Aminoverse enables clients to accelerate and de-risk enzyme innovation in the early value chain from target reaction to tailored enzyme.
Founded in 2020 by a team of entrepreneurs and scientists with >35 years of experience, Aminoverse’s CRO services combine enzyme wet lab expertise with in silico design and its recently launched proprietary AI technologies “EnzyMAP” and “EnzyREC”. Clients include large pharmaceutical and biotech companies as well as start-ups worldwide.
For biocatalysis, Aminoverse offers the world’s largest collections of unspecific peroxygenases and ketoglutarate-dependent oxygenases for rapid hit screening – free or 3rd party IP and scalable.
Aminoverse is the go-to enzyme R&D partner for successful enzyme discovery and next generation enzyme engineering.